NCT03485378View on ClinicalTrials.gov

Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease

NAActive, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 20, 2018

Primary Completion Date

January 11, 2022

Study Completion Date

September 20, 2026

Conditions
Non Small Cell Lung CancerInterstitial Lung Disease
Interventions
RADIATION

Stereotactic Ablative Radiotherapy

Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease

Trial Locations (6)

T6G 1Z2

Alberta Health Services, Cross Cancer Institude, Edmonton

N6A 4L6

London Regional Cancer Program of the Lawson Health Research Institute, London

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

M5G 2M9

UHN Princess Margaret Cancer Centre, Toronto

H2X 0A9

CHUM Université de Montréal, Montreal

EH4 2XU

Edinburgh Cancer Centre, Western General Hospital, Edinburgh

Sponsors
All Listed Sponsors
collaborator

London Health Sciences Centre

OTHER

collaborator

University of British Columbia

OTHER

collaborator

Western University, Canada

OTHER

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT03485378 - Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease | Biotech Hunter | Biotech Hunter